Kaleido Biosciences Inc represents a strong commitment to advancing the field of microbiome therapeutics. With a focus on leveraging the potential of the microbiome to address various diseases, Kaleido Biosciences aims to provide innovative solutions for patients worldwide. The company's corporate philosophy revolves around rigorous scientific research, collaboration, and a patient-centric approach. By harnessing the power of the human microbiome, Kaleido Biosciences seeks to develop novel therapies that can restore and maintain health. This dedication to groundbreaking microbiome science and its application in drug development defines Kaleido Biosciences Inc and its mission to improve patient outcomes.

Kaleido Biosciences Inc is primarily present in the United States.

Kaleido Biosciences Inc has achieved significant milestones in its journey. The company has successfully advanced its Microbiome Metabolic Therapies (MMT™) platform, which aims to harness the potential of the human microbiome to develop novel treatments for various diseases. One notable achievement is the initiation of clinical trials for multiple candidates, including KB195 and KB174, targeting hyperammonemia and hepatic encephalopathy, respectively. Kaleido Biosciences has also forged strategic collaborations with renowned organizations such as Johnson & Johnson Innovation and Pfizer, further validating its innovative approach. These achievements highlight Kaleido Biosciences' commitment to exploring the therapeutic potential of the microbiome to benefit patient health.

Kaleido Biosciences Inc, founded in 2015, is a clinical-stage healthcare company based in Massachusetts, United States. Focusing on the development of novel, chemistries-based medicines, Kaleido Biosciences aims to address the underlying causes of various diseases. The company's proprietary Microbiome Metabolic Therapy (MMT™) platform harnesses the potential of the human microbiome to create potential therapeutic approaches. Kaleido Biosciences believes that the human microbiome has a significant impact on overall health and disease. By modulating the function of the microbiome, the company endeavors to provide targeted treatments for various conditions, including metabolic and neurological disorders. Kaleido Biosciences is committed to advancing its pipeline and delivering innovative healthcare solutions.

Some of the main competitors of Kaleido Biosciences Inc in the market include companies such as Microbiome Therapeutics LLC, Seres Therapeutics Inc, and Rebiotix Inc.

Kaleido Biosciences Inc is primarily active in the biotechnology industry.

Kaleido Biosciences Inc's business model focuses on utilizing its Microbiome Metabolic Therapeutics (MMT™) platform to develop a range of therapies for various diseases. By leveraging the potential of the microbiome, Kaleido aims to address unmet medical needs through proprietary chemistries and targeted interventions. Kaleido Biosciences Inc aims to harness the power of the microbiome's impact on specific disease pathways to revolutionize the treatment landscape. Through its innovative approach, the company aims to bring about novel therapeutic options for patients, highlighting the potential of the microbiome in improving human health.

Kaleido Biosciences의 P/E 비율은 -0입니다.

Kaleido Biosciences의 P/S 비율은 0입니다.

Kaleido Biosciences에 대한 AlleAktien 품질 점수는 2/10입니다.

예상되는 Kaleido Biosciences 매출은 31.5 백만 USD입니다.

예상되는 Kaleido Biosciences 이익은 -49.89 백만 USD입니다.

Kaleido Biosciences Inc. is a biotherapeutic company focused on understanding and manipulating the microbiome to treat chronic and serious diseases. The company is based in Lexington, Massachusetts, USA and was founded in 2015. Kaleido Biosciences' business model involves identifying and developing novel therapeutic solutions based on the targeted manipulation of the microbiota. The main strategy is to optimize the body's ability to heal and regenerate by optimizing the physiological and metabolic functions of the gut microbiome. The company also has a pipeline of clinical trials for its key programs in microbiome-mediated therapy and microbiome-modulated immunotherapy. Kaleido Biosciences' products are marketed under the name Microbiome Metabolic Therapies (MMTTM) and include a range of drugs and supplements. The company has a team of executives and scientists focusing on discovering and developing new therapy options for various diseases, and has filed numerous patents to protect its technology platform. Overall, Kaleido Biosciences' business model offers a promising solution for the treatment of chronic and serious diseases through microbiome manipulation, with a wide range of products and strong growth potential indicated by its clinical trial pipeline.

Kaleido Biosciences은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Kaleido Biosciences의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Kaleido Biosciences의 ISIN은 US4833471000입니다.

Kaleido Biosciences의 WKN은 A2PELT입니다.

Kaleido Biosciences의 티커는 KLDO입니다.

지난 12개월 동안 Kaleido Biosciences은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Kaleido Biosciences은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Kaleido Biosciences의 현재 배당 수익률은 입니다.

Kaleido Biosciences은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Kaleido Biosciences은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Kaleido Biosciences은 '건강' 섹터에 속합니다.

Kaleido Biosciences의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Kaleido Biosciences는 0 USD를 배당금으로 지급했습니다.

Kaleido Biosciences의 배당금은 USD에 지급됩니다.